Objective: To study the impact of occult hepatitis B virus (HBV) infection in 115 consecutive anti-HIV-positive, hepatitis B surface antigen-negative patients, naive for antiretroviral treatment.
Introduction
Sensitive polymerase chain reaction (PCR) assays detect hepatitis B virus (HBV) DNA in plasma and liver tissue of both hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative individuals [1] [2] [3] . 'Occult' or 'silent' HBV infection are the terms currently used to identify the detection of HBV DNA in HBsAg-negative patients [4] [5] [6] . Mason et al. [7] demonstrated that HBV replication may persist for years in the livers of HBsAg-negative patients after they have recovered from acute HBV infection, because they found both HBV transcription and an intact direct repeat region of HBV DNA in the livers of HBsAg-negative patients 3-67 months after acute hepatitis B infection.
Several studies have given evidence of the presence of low-level HBV replication in patients with chronic hepatitis C virus (HCV) with or without antibodies to the HBV antigens [1, 2, [4] [5] [6] . Patients with chronic HCV and occult HBV infection more frequently have a severe liver disease [8] , lack of response to interferon treatment [9, 10] , and a higher risk of developing hepatocellular carcinoma [11, 12] than those with chronic HCV alone.
Studies on the prevalence of occult HBV infection in anti-HIV-positive patients have been performed, but conflicting data are reported [13, 14] .
Several reports have described a reactivation of HBV replication in HBsAg/anti-HIV-negative individuals receiving prednisone or chemotherapy, followed by a hepatic flare after the discontinuation of treatment that is at times severe or even fatal [15] [16] [17] . It is very difficult in anti-HIV-positive patients with occult HBV infection to attribute a hepatic flare to changes in HBV replication as a result of the development of HBV mutants under lamivudine or tenofovir treatment or after the discontinuation of these drugs [18, 19] , because HAART [20] [21] [22] and immune reconstitution inflammatory syndrome (IRIS) [23, 24] may both cause hepatic flares. The identification of the cause of a hepatic flare in these patients is, however, of clinical relevance because clinical and therapeutic decisions should be based on the pathogenesis of the flare. Therefore, we studied occult HBV infection in a multicentre prospective study on 115 consecutive anti-HIV-positive, HBsAg-negative patients, naive for HIV treatment at the beginning of the observation. The patients were enrolled in five wards of infectious diseases in southern Italy and were followed for at least 6 months (median 18, range 6-36) to monitor for changes in HBV replication and hepatic flares.
Patients and methods
Five wards of infectious diseases in southern Italy, two in the Campania region (one in Naples and one in Caserta), two in Basilicata (Potenza and Matera), and one in Calabria (Catanzaro), participated in the study. These five centres have cooperated in several clinical investigations using the same laboratory methods and the same clinical approach. The study was planned as an observational prospective study by all the investigators during a preliminary consensus meeting.
Enrolment started in February 2001 and ended one year later; 115 consecutive anti-HIV-positive, HBsAgnegative patients naive for antiretroviral therapy were included.
Throughout the observation, the anti-HIV-positive patients (HIV subjects) were left untreated or received treatment according to the current international guidelines [25, 26] .
For all patients a no-end follow-up was planned. A total of 86 patients were observed monthly as outpatients in one of the five participating clinical centres for at least 6 months (median 18, range 6-36), whereas 29 were lost to follow-up because of lack of compliance. No significant difference was observed between the 86 patients having a follow-up and the 29 who were lost to follow-up with regard to demographic, clinical and laboratory characteristics observed on admission. Of the 86 patients with follow-up, 21 did not receive antiretroviral treatment, 38 received protease inhibitor-based antiretroviral therapy, 14 received non-nucleoside reverse transcriptase inhibitor-based treatment, 11 received both protease inhibitors and non-nucleoside reverse transcriptase inhibitors, and the remaining two received a three nucleoside reverse transcriptase inhibitor regimen. None of the 86 patients with a follow-up was treated with tenofovir or emtricitabine. No patient received chemotherapy during the observation period.
For each patient serum and plasma samples were obtained at the time of the first observation and then every 3 months during the follow-up. The samples were stored at À808C and not thawed until used for this investigation. The patient's informed consent was always obtained.
The stage of HIV infection and related diseases was defined according to the Centers for Disease Control classification published in 1993 [27] .
Patients were considered as having a 'hepatic flare' when they showed an increase in the serum alanine aminotransferase value of at least three times the previous value. Risk factors for a hepatic flare were recorded throughout the follow-up: the presence of plasma HBV DNA, alcohol intake, intravenous drug abuse, HAART (ritonavir or nevirapine, in particular), and lamivudine treatment or its discontinuation.
Patients were considered as having IRIS if the Shelburne criteria were fulfilled [23, 24] : an antiretroviral therapyinduced increase in the CD4 cell counts or a decrease in the HIV-RNA plasma level in patients with AIDS showing symptoms consistent with an infectious/ inflammatory condition appearing while on ART, which may not be explained by an expected course of a previously recognized infection, or by the side-effects of treatment.
HBV viraemia was determined in all the HBsAg-negative plasma samples by a qualitative PCR, extensively described in previous papers [2, 8, 9] . Briefly, viral DNA was extracted from 200 ml of each plasma specimen using microspin columns (QIAamp blood kit, Qiagen GmbH, Hilden, Germany) and then amplified using primers located in the core region of HBV (upstream primer 5 0 -TTGCCTTCTGACTTCTTTCC-3 0 , nucleotides 1955-1974, and downstream primer 5 0 -TCTGCG AGGCGAGGGAGTTCT-3 0 , nucleotides 2401-2381). PCR was performed in a programmable thermal cycler (Perkin Elmer 9700; Perkin Elmer, USA) with the following three-step cycling profile: 938 for 30 s, 488 for 30 s, 688 for 60 s, for a total of 35 cycles. The amplified product was detected by hybridization with a specific probe in the core region (GEN-ETI-K HBV core; DiaSorin Biomedica Saluggia, VC, Italy). Sample preparation and DNA extraction were carried out in a different room from the one in which the amplified samples were handled, and a filter pipette was used for all steps. Positive (plasma sample of HBeAg-positive patients) and negative (DNA/RNA-free water) were included in all runs of extraction and amplification; moreover, a negative control was included after every 10 samples to minimize possible contamination. To evaluate the sensitivity of our PCR, serial dilutions of a control specimen with a known HBV viral load (100 000 copies/ ml) were made until a dilution of 10 copies/ml was obtained. The lowest limit of detection by this method is 100 copies/ml.
In HBV-DNA-positive plasma samples the viral load was determined by quantitative PCR using the HBV Amplicor Monitor (Roche Molecular Systems, Branchburg, New Jersey, USA); the lowest limit of HBV-DNA detection of this method is 600 copies/ml.
HBsAg-negative subjects were considered as carrying occult HBV infection if HBV DNA was detected in the plasma first by the qualitative PCR assay and then by the quantitative PCR; in the patients who were HBV-DNA positive by the qualitative PCR and negative by the less sensitive quantitative assay, a qualitative PCR was repeated and the previous positive results were always confirmed.
In plasma samples obtained from patients who became HBV-DNA positive at the time a hepatic flare occurred under lamivudine treatment, mutations in the HBV-DNA polymerase gene (YMDD motif) were determined by PCR and direct sequencing using forward primer 5 0 -GCCCGTTTGTCCTCTACT-3 0 (nucleotides466-483) and reverse primer CAAAACAAAAAGATGGG GATA (nucleotides 843-863) (accession no. AB205190) [28] . Briefly, PCR products were purified using a QIA quick kit (Qiagen) and sequenced using an autosequencer (CEQ 8000 autosequencer; Beckman Coulter, Fullerton, California, USA).
Antibodies to HIV-1 and HIV-2 were determined by commercial enzyme-linked immunosorbent assay (Abbott Laboratories, North Chicago, Illinois, USA and DiaSorin Biomedica), and the reactivity of samples was confirmed by a Western blot analysis (Genelabs Diagnostics, Science Park Drive, Singapore), which identifies both HIV-1 and HIV-2 strains.
HBV serum markers were detected using commercial immunoenzymatic assays [Abbott Laboratories for HBsAg, anti-hepatitis B surface (HBs) and anti-hepatitis B core (HBc), and DiaSorin Biomedica for hepatitis B e antigen and anti-hepatitis B e). The anti-HCV antibodies were determined using a third-generation commercial immunoenzymatic assay (Ortho Diagnostic Systems, Neckargemund, Germany). Antibodies to the hepatitis A virus (total and IgM) were determined using a commercial immunoenzymatic assay (Abbott Laboratories).
The lymphocyte subsets (CD4, CD8) were assessed by flow cytofluorimetry using monoclonal antibodies and fluorescence-activated cell sorter scan (Becton Dickinson, Mountain View, USA). Liver function tests were performed by routine methods every month.
The mean values were compared using the Student's t-test, the differences in the proportions were assessed by the x 2 test with the Yates correction or by Fisher's exact test. A P value less than 0.05 was considered to be statistically significant.
Results
Of the 115 anti-HIV-positive subjects, 57 were anti-HBs negative/anti-HBc negative (group A), 16 were anti-HBs positive/anti-HBc positive (group B), and 42 were antiHBs negative/anti-HBc positive (group C). Table 1 shows the demographic, clinical and laboratory data recorded on admission for the 115 patients, according to the presence or absence of antibodies to HBV. No significant difference was observed in these three groups of patients with regard to age, sex, presumed median duration of HIV infection, risk factors for the acquisition of both HIVand HBV infections, CD4 cell count, alanine aminotransferase and clinical stage of HIV infection (Table 1) . Patients in group A (28.1% of 57 cases) less frequently than those in group C (50% of 42, P < 0.05) or B (43.7% of 16) were anti-HCV positive.
Plasma HBV DNA was detected in 18 patients at the time of the first observation and in another four during the follow-up. Of these 22 HBV-DNA-positive patients by the qualitative assay, 10 had an undetectable viral load and 12 a low viral load (from 7.4 Â 10 2 to 3.5 Â 10 3 copies/ml).
Considering the 86 patients in the follow-up study, 17 were found to be HBV-DNA positive, 13 on admission and four in the subsequent observation: these HBV-DNA-positive patients were less frequent (three of 41, 8.8%) in the anti-HBs-negative/anti-HBc-negative group (group A 1 ) than in the anti-HBs-positive/antiHBc-positive group (group B 1 ; three of 14, 21.4%) and in the anti-HBs-negative/anti-HBc-positive group (group C 1 ; 11 of 31, 35.5%, P < 0.005).
The CD4 cell count (mean AE SD) was 380 AE 270 in HBV-DNA-positive patients and 290 AE 212 in HBV-DNA-negative subjects, a difference that was not significant to the statistical analysis. Moreover, HBV DNA was detected in 4.5% of the 22 patients with a CD4 cell count greater than 500 cells/ml and in 25% of the 64 subjects with a CD4 cell count lower than 500 cells/ml; this difference was also not statistically significant.
Of the 86 patients with a follow-up, 28 (32.5%) experienced a hepatic flare (Table 2) ; this occurred more frequently in the 17 patients with occult HBV infection than in the 69 HBV-DNA-negative patients (64.7 versus 24.6%; P < 0.005). No correlation was found between the HBV viral load and the occurrence of a hepatic flare in patients with a detectable HBV viral load.
In most patients with a flare more than one risk factor for its occurrence was recorded (Table 2) ; a multivariate analysis, however, was not performed because of the numerous risk factors and the relatively low number of patients. Of the 28 patients experiencing a hepatic flare during the follow-up, 18 were anti-HCV positive and 10 were anti-HCV negative; none of these 10 developed acute HCV during the observation.
Of the 13 patients who were HBV-DNA positive on admission, two did not receive HAART; one of these two experienced a hepatic flare after a 12-month observation (Fig. 1a) . The other 11 patients were treated with HAART containing lamivudine and were HBV-DNA negative at the subsequent check points. Of these 11, four (Fig. 1b-e) became HBV-DNA positive under lamivudine treatment and experienced a hepatic flare; two of these four also experienced a hepatic flare after the discontinuation of the drug (Fig. 1d, e) . Another two of these 11 patients (Fig. 1f, g ) became HBV-DNA positive and experienced a hepatic flare, respectively, 4 and 8 months after lamivudine was discontinued because of lack of efficacy of the HAART regimen. The remaining five patients of the 11 treated remained HBV-DNA negative under HAART containing lamivudine and did not experience a hepatic flare. Of the four patients who were HBV-DNA negative on admission and positive during the observation, two (Fig. 1h, i) had been receiving HAART including lamivudine for 12 and 16 months, respectively, when they became HBV-DNA positive and experienced a hepatic flare; the remaining two patients (Fig. 1j, k) were never treated with lamivudine, became HBV-DNA positive and experienced a hepatic flare after 18 and 9 months of observation, respectively.
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All patients who became HBV-DNA positive by the qualitative assay during the follow-up showed an undetectable or very low HBV viral load (6.8 Â 10 2 to 1.1 Â 10 3 copies/ml). The YMDD mutant was never observed in the six patients who became HBV-DNA positive during lamivudine treatment; four of these six, however, showed an undetectable HBV viral load and two a very low viral load (6.8 Â 10 2 and 8.1 Â 10 2 copies/ml).
The role of HAART and IRIS in the development of flares was analysed in the 49 patients lacking the confounding effects of the hepatitis viruses (anti-HCV negative and HBsAg/HBV-DNA negative). A hepatic flare was found in none of the 13 patients who remained untreated during the follow-up, in 26.3% of the 19 receiving HAART and showing signs of IRIS, and in 11.8% of the 17 patients receiving HAART with no evidence of IRIS.
Discussion
Contrasting data are reported in the literature on the prevalence of occult HBV infection in anti-HIV-positive individuals: Nunez et al.
[13] 0%, Neau et al. [29] 0.6%, Shire et al. [30] 10.5% and Hofer et al. [14] 89.5%. Differences in the patient selection (i.e. age, sex, risk factor for the acquisition of HBV infection, degree of immunodepression), in the percentage of patients receiving HAART containing lamivudine or tenofovir, and differences in the sensitivity of the PCR assays used might account for these discrepancies.
Using a sensitive PCR assay we found an occult HBV infection in approximately 20% of anti-HIV-positive/ HBsAg-negative consecutive patients, naive for antiretroviral therapy on admission. Worthy of mention is the observation that four patients in this study were HBV-DNA negative on admission and HBV-DNA positive during the follow up, suggesting that fluctuations in HBV replication may occur, and that serial determinations of HBV DNA are required to identify occult HBV infection.
The presence of HBV antibodies in HBsAg-negative subjects is generally used in epidemiological studies as a marker of a previous HBV infection. However, the growing knowledge on the immune response to HBV seems to indicate that these antibodies are involved in the immune regulation exerted by the host on HBV replication [31] . Consistent with this are several studies on anti-HIV-negative/HCV-RNA-positive cases showing an association between occult HBV infection and the presence of the HBV antibody [1, 2, 4, 32] . The present study, performed on anti-HIV-positive subjects, shows that approximately one third of cases with antibodies to HBV had detectable plasma HBV DNA, whereas the circulating HBV genome was rarely found in anti-HBs/ anti-HBc-negative individuals, most of whom had possibly never become infected with HBV.
Lamivudine-based HAART is effective in suppressing HBV replication even in anti-HIV-positive patients with occult HBV infection, because most cases with occult HBV infection cleared HBV DNA during treatment. However, in approximately half of the lamivudinetreated patients occult HBV replication became detectable again after 12-40 months of lamivudine treatment, always associated with a hepatic flare. Although YMDD mutants were not detected in patients who became HBV-DNA positive during lamivudine treatment, the question of whether lamivudine may induce the selection of YMDD mutants also in occult HBV infection in anti-HIV-positive subjects still remains unanswered, because the HBV-DNA plasma levels in these cases were too low to allow detection. Similar to what is observed in HBsAgpositive subjects, both anti-HIV positive and negative [33] [34] [35] , the discontinuation of lamivudine in HIV patients with occult HBV infection may be followed by reconversion to HBV-DNA positivity associated with a hepatic flare.
After the introduction of HAART, drug-induced hepatotoxicity has emerged as an important complication of antiretroviral treatment [20] [21] [22] , the most frequent mechanisms of liver damage being a direct cytopathic effect of the drugs or mitochondrial toxicity and steatosis, or IRIS [23, 24] . However, this study of hepatic flares in anti-HIV-positive subjects with no HBV or HCV serum marker shows that hepatic flares may be ascribed to the toxicity of HAARTor to IRIS only in a small percentage of patients. Instead, a hepatic flare was found three times more frequently in patients with occult HBV infection than in those without.
In conclusion, HBV occult infection seems to be relatively frequent in anti-HIV-positive patients and may induce hepatic flares, even under lamivudine treatment or when this drug is discontinued. 
